Guardian Pharmacy price target raised to $28 from $25 at Truist

Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $28 from $25 and keeps a Buy rating on the shares. The firm is adjusting its model following the company’s Q1 results while citing its leading positioning in the fragmented long-term care pharmacy industry, which carries “brisk overarching secular demand drivers”, the analyst tells investors in a research note. Guardian also provides an attractive offering for patients, facilities and payors looking to improve outcomes and lower costs, and the firm is positive on its strategy geared toward the attractive assisted living and behavioral health settings, Truist added.